🇺🇸 FDA
Pipeline program

PDR001

CPDR001X2102

Phase 1 mab completed

Quick answer

PDR001 for Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma is a Phase 1 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials